Rapid Medical Donation Programme for Breast Cancer (LEGACY)
Rapid Medical Donation Programme for Breast Cancer to Examine Tumour Heterogeneity
Treatment of breast cancer has traditionally been based on the primary tumour's features in the breast. Only recently, when cancer returns at other sites, has there been an attempt to biopsy the metastatic disease and change treatments accordingly. A 'repeat biopsy' can be technically difficult, painful and, when possible, only represents a small sample of one of many metastases.
Even when one deposit responds to a new treatment, a neighbouring one may continue to grow. There is an urgent need to characterise all deposits, particularly the lethal ones which progress despite all treatments.
This study will enable the comprehensive analysis of the metastatic process and the evolution of the breast cancer through the course of its treatment. Patients who have consented during life to donate their tissues for molecular analysis will provide the means for such an analysis.
Main aims:
- To comprehensively and systematically examine metastatic breast cancer by its detailed exploratory molecular characterization to elucidate the possible inter- and intratumoural heterogeneity between the primary tumour and the majority of metastatic sites.
- To map the natural history of the metastatic breast cancer process
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Lieux d'étude
-
-
-
London, Royaume-Uni, SW3 6JJ
- Recrutement
- Royal Marsden NHS Foundation Trust
-
Contact:
- Sally Bennett, RN
- Numéro de téléphone: +44 (0)20 7153 5004
- E-mail: LEGACY-BC@icr.ac.uk
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Patients who have completed active treatment (or trials) for metastatic breast cancer.
- Patients referred to either community or the hospital-based palliative care unit from Royal Marsden National Health Service Foundation Trust.
Exclusion Criteria:
- Lack of capacity / inability to give informed consent.
- Diagnosis of alternative cancer within the last 5 years other than resected basal cell skin cancer or cervical intraepithelial neoplasia.
- Patients known to be HIV, Hepatitis B virus or Hepatitis C virus positive on serology .
- Spongiform encephalopathy (known or suspected CJD) .
- Eligibility for or current participation in a clinical trial (excluding palliative care trials)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
The acquisition of tumour tissue from multiple metastatic sites.
Délai: Within 6 hours from the time of death.
|
Within 6 hours from the time of death.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Peter A Barry, MB BS, Royal Marsden NHS Foundation Trust
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CCR3995
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .